{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.2","upperLimit":"15.2","value":"9.5"},{"groupId":"OG001","lowerLimit":"18.7","upperLimit":"46.5","value":"26.4"},{"comment":"insufficient number of participants with event to calculate upper limit and median per K-M methodology","groupId":"OG002","lowerLimit":"18.6","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"112"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"description":"PFS is defined as the time from the first dose to the first documentation of disease progression according to modified International Myeloma Working Group (mIMWG) criteria or death from any cause, whichever occurs first.\n\nDisease Progression=Increase or reappearance of monoclonal protein in serum or urine meeting mIMWG progression thresholds; Increase in bone marrow plasma cell percentage consistent with disease progression; Development of new or worsening lytic bone lesions; Progressive or newly enlarging extramedullary plasmacytomas. Based on Kaplan-Meier Estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"(Pomalidomide + low dose Dexamethasone) in participants with 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old).","id":"OG000","title":"Cohort A"},{"description":"(Pomalidomide + Daratumumab + low dose Dexamethasone) in participants with 1 or 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old). DARA was administered intravenously (IV) at a starting dose of 16 mg/kg.","id":"OG001","title":"Cohort B"},{"description":"(Pomalidomide + Daratumumab + low dose Dexamethasone) in Japanese participants with 1 or 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old). DARA was administered intravenously (IV) at a starting dose of 16 mg/kg.","id":"OG002","title":"Cohort C"}],"paramType":"MEDIAN","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose until the first documented disease progression, or death whichever occurs first (Up to 130 months)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}